Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells $1,206,004.59 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 27,279 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the transaction, the chief executive officer now owns 138,641 shares of the company’s stock, valued at approximately $6,129,318.61. This represents a 16.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 3rd, Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total transaction of $438,898.44.
• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98.

Mirum Pharmaceuticals Trading Down 1.9 %

NASDAQ:MIRM opened at $44.31 on Wednesday. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $54.23. The firm has a market cap of $2.17 billion, a PE ratio of -21.94 and a beta of 1.04. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a fifty day moving average price of $47.55 and a 200 day moving average price of $43.60.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $99.41 million during the quarter, compared to analysts’ expectations of $96.64 million. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. lifted its position in shares of Mirum Pharmaceuticals by 1.2% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after purchasing an additional 75,000 shares during the last quarter. Janus Henderson Group PLC raised its stake in Mirum Pharmaceuticals by 2.3% in the fourth quarter. Janus Henderson Group PLC now owns 4,581,642 shares of the company’s stock valued at $189,481,000 after buying an additional 101,358 shares in the last quarter. State Street Corp boosted its position in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Mirum Pharmaceuticals by 10.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company’s stock valued at $58,831,000 after acquiring an additional 138,623 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Mirum Pharmaceuticals by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 943,344 shares of the company’s stock worth $39,016,000 after acquiring an additional 7,147 shares in the last quarter.

Analyst Upgrades and Downgrades

MIRM has been the topic of a number of research analyst reports. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. HC Wainwright boosted their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Buy” and an average price target of $58.20.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.